Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Ann Surg. 2018 May;267(5):797–805. doi: 10.1097/SLA.0000000000002574

Figure 4.

Figure 4

Intention-to-treat analysis. (A)Comparing all patients enrolled in a transplant protocol (n=66) to all patients who underwent attempted resection with tumors <3cm and no lymph node disease (N0) on pathologic examination (n=58). Median overall survival among transplant patients was 77.4 months, and 1-, 3-, and 5-year survivals were 80%, 58%, and 53%, respectively. Median overall survival among resection patients was 27.4 months (95% CI, 5.5–49.3), and 1-, 3-, and 5-year survivals were 73%, 46%, 29%, respectively (log rank p=0.002). (B) Comparing all non-PSC patients enrolled in a transplant protocol (n=35) to all patients who underwent attempted resection with tumors <3cm and N0 disease on pathologic examination (n=57). Median overall survival among transplant patients was 32.5 months (95% CI, 13.5–51.5), and 1-, 3-, and 5-year survivals were 82%, 46%, and 41%, respectively. Median overall survival among resection patients was 27.4 months (95% CI, 6.0–48.8), and 1-, 3-, and 5-year survivals were 72%, 45%, and 27%, respectively (log rank p=0.049).